Fig. 3: Kaplan–Meier analysis of the overall survival (OS), progression-free survival (PFS), and duration of response (DOR). | Nature Communications

Fig. 3: Kaplan–Meier analysis of the overall survival (OS), progression-free survival (PFS), and duration of response (DOR).

From: Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

Fig. 3

a Kaplan–Meier curves of OS in all 50 patients. b Kaplan–Meier curves of PFS in all 50 patients. c Kaplan–Meier curves of DOR in 46 patients with a partial or better response. Tick marks indicate the time of data censoring at the last follow-up. NE not estimated. DOR, PFS, and OS of patients were determined using Kaplan–Meier and compared using the log-rank test. Source data are provided in the Source Data file.

Back to article page